Opdualag

OPDUALAG (nivolumab + relatlimab-rmbw) is a fixed-dose combination of two immune checkpoint inhibitors: Nivolumab: Anti–PD-1 monoclonal antibody, blocking PD-1 interaction with PD-L1/PD-L2, enhancing T-cell anti-tumor response. Relatlimab: Anti–LAG-3 monoclonal antibody, promoting T-cell activation, proliferation, and cytokine secretion. <a id="